Cipla’s distribution edge turns Lilly-licensed Tirzepatide brand into growth machine

Cipla's Yurpeak brand, licensed by Eli Lilly, sells the diabetes drug Tirzepatide.

Yurpeak achieved its highest-ever monthly sales of Rs.27.4 crore in June.

Yurpeak's market share increased to 15.7% in June from 10.9% in January.

Eli Lilly's own brand Mounjaro holds the dominant market position for Tirzepatide.